Etidronate for the primary and secondary prevention of osteoporotic fractures in postmenopausal women

Cochrane Database of Systematic Reviews

Volumn , Issue 1, 2008, Pages

  Wells, George A ^a   Cranney, A ^b   Peterson, J ^b   Boucher, M ^b   Shea, B ^b   Robinson, V ^b   Coyle, D ^b   Tugwell, P ^b  

^a UNIVERSITY OF OTTAWA HEART INSTITUTE   (Canada)

^b NONE

Author keywords

Bone density drug effects ; Etidronic acid *therapeutic use ; Female; Humans; Osteoporosis, postmenopausal *drug therapy; prevention control ; Spinal fractures etiology

Indexed keywords

ALENDRONIC ACID; CALCITRIOL; CALCIUM; ETIDRONIC ACID; RISEDRONIC ACID; VITAMIN D; BONE DENSITY CONSERVATION AGENT; DRUG DERIVATIVE;

ABDOMINAL CRAMP; ABDOMINAL PAIN; ARTHRALGIA; BACKACHE; BONE DENSITY; BONE PAIN; CARDIOVASCULAR DISEASE; CENTRAL NERVOUS SYSTEM DISEASE; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; DIARRHEA; DIZZINESS; DRUG EFFICACY; DRUG TOLERABILITY; DRUG WITHDRAWAL; ENDOCRINE DISEASE; FOLLOW UP; FRAGILITY FRACTURE; GASTROINTESTINAL DISEASE; HEARING DISORDER; HEMATOLOGIC DISEASE; HIP FRACTURE; HUMAN; INFECTION; KIDNEY DISEASE; LOW BACK PAIN; META ANALYSIS; MUSCULOSKELETAL DISEASE; NAUSEA; POSTMENOPAUSE; PROPHYLAXIS; RANDOMIZED CONTROLLED TRIAL; RESPIRATORY TRACT DISEASE; REVIEW; RISK FACTOR; SKIN DISEASE; SYSTEMATIC REVIEW; TREATMENT OUTCOME; URINARY TRACT DISEASE; VERTEBRA FRACTURE; VISUAL DISORDER; FEMALE; FRACTURE; POSTMENOPAUSE OSTEOPOROSIS; SPINE FRACTURE;

BONE DENSITY CONSERVATION AGENTS; ETIDRONIC ACID; FEMALE; FRACTURES, BONE; HIP FRACTURES; HUMANS; OSTEOPOROSIS, POSTMENOPAUSAL; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SPINAL FRACTURES;

EID: 41949137898     PISSN: 1469493X     EISSN: None     Source Type: Journal    
DOI: 10.1002/14651858.CD003376.pub3     Document Type: Review

References (85)

1. Herd 1997 {published data only} *Herd RJ, Balena R, Blake GM, Ryan PJ, Fogelman I. The prevention of early postmenopausal bone loss by cyclical etidronate therapy: a 2-year, double-blind, placebo-controlled study. American Journal of Medicine 1997;103(2):92-9.
2. Ishida 2004 {published data only} *Ishida Y, Kawai S. Comparative efficacy of hormone replacement therapy, etidronate, calcitonin, alfacalcidol, and vitamin K in postmenopausal women with osteoporosis: The Yamaguchi Osteoporosis Prevention Study. American Journal of Medicine 2004;117(8):549-55.
3. Lyritis 1997 {published data only} *Lyritis GP, Tsakalakos N, Paspati I, Skarantavos G, Galanos A, Androulakis C. The effect of a modified etidronate cyclical regimen on postmenopausal osteoporosis: a four-year study. Clinical Rheumatology 1997;16(4):354-60.
4. Meunier 1997 {published data only} *Meunier PJ, Confavreux E, Tupinon I, Hardouin C, Delmas PD, Balena R. Prevention of early postmenopausal bone loss with cyclical etidronate therapy (a double-blind, placebo-controlled study and 1-year follow-up) [see comment] [erratumappears in JClin Endocrinol Metab 1997 Nov;82(11):3740]. Journal of Clinical Endocrinology and Metabolism 1997;82(9):2784-91.
5. Montessori 1997 {published data only} *Montessori ML, Scheele WH, Netelenbos JC, Kerkhoff JF, Bakker K. The use of etidronate and calcium versus calcium alone in the treatment of postmenopausal osteopenia: results of three years of treatment. Osteoporosis International 1997;7(1):52-8.
6. Pacifici 1988 {published data only} *Pacifici R, McMurtry C, Vered I, Rupich R, Avioli LV. Coherence therapy does not prevent axial bone loss in osteoporotic women: a preliminary comparative study. Journal of Clinical Endocrinology and Metabolism 1988;66(4):747- 53.
7. Pouilles 1997 {published data only} *Pouilles JM, Tremollieres F, Roux C, Sebert JL, Alexandre C, Goldberg D, et al.Effects of cyclical etidronate therapy on bone loss in early postmenopausal women who are not undergoing hormonal replacement therapy. Osteoporosis International 1997;7(3):213-8.
8. Shiota 2001 {published data only} *Shiota E, Tsuchiya K, Yamaoka K, Kawano O. Effect of intermittent cyclical treatment with etidronate disodium (HEBP) and calcium plus alphacalcidol in postmenopausal osteoporosis. Journal of Orthopaedic Science 2001;6(2):133-6.
9. Storm 1990 {published data only} Storm T, Thamsborg G, Steiniche T, Genant HK, Sorensen OH. Effect of intermittent cyclical etidronate therapy on bone mass and fracture rate in women with postmenopausal osteoporosis [see comment]. New England Journal of Medicine 1990;322(18):1265- 71.
10. Watts 1990 {published data only} *Watts NB, Harris ST, Genant HK, Wasnich RD, Miller PD, Jackson RD, et al.Intermittent cyclical etidronate treatment of postmenopausal osteoporosis [see comment]. New England Journal of Medicine 1990;323(2):73-9.
11. Watts 1990A {published data only} Watts NB, Harris ST, Genant HK, Wasnich RD, Miller PD, Jackson RD, et al.Intermittent cyclical etidronate treatment of postmenopausal osteoporosis [see comment]. New England Journal of Medicine 1990;323(2):73-9.
12. Watts 1990B {published data only} Watts NB, Harris ST, Genant HK, Wasnich RD, Miller PD, Jackson RD, et al.Intermittent cyclical etidronate treatment of postmenopausal osteoporosis [see comment]. New England Journal of Medicine 1990;323(2):73-9.
13. Wimalawansa 1998 {published data only} *Wimalawansa SJ. A four-year randomized controlled trial of hormone replacement and bisphosphonate, alone or in combination, in women with postmenopausal osteoporosis. American Journal of Medicine 1998;104(3):219-26.
14. Adami 2000 Adami S, Bruni V, Bianchini D, Becorpi A, Lombardi P, Campagnoli C, et al.Prevention of early postmenopausal bone loss with cyclical etidronate. Journal of Endocrinological Investigation 2000;23(5):310-6.
15. Anderson 1984 Anderson C, Cape RD, Crilly RG, Hodsman AB, Wolfe BM. Preliminary observations of a form of coherence therapy for osteoporosis. 1984;36(3):341-3.
16. Bolanca 1988 Bolanca S, Korsic M, Dekanic D, Cvijetic S. Effects of combined treatment with etidronate, nandrolone-decanoate and calcium on bone mineral density in postmenopausal women. Acta Medica Croatica 1998;52(3):159-63.
17. Chilibeck 2002 *Chilibeck PD, Davison KS, Whiting SJ, Suzuki Y, Janzen CL, Peloso P. The effect of strength training combined with bisphosphonate (etidronate) therapy on bone mineral, lean tissue, and fat mass in postmenopausal women. Canadian Journal of Physiology and Pharmacology 2002;80(10):941-50.
18. Cortet 2001 Cortet B, Bera-Louville A, Gauthier P, Gauthier A, Marchandise X, Delcambre B. Comparative efficacy and safety study of etidronate and alendronate in postmenopausal osteoporosis. effect of adding hormone replacement therapy. Joint, Bone, Spine: Revue du Rhumatisme 2001;68(5):410-5.
19. Evans 1993 Evans RA, Somers NM, Dunstan CR, Royle H, Kos S. The effect of low-dose cyclical etidronate and calcium on bone mass in early postmenopausal women. Osteoporosis International 1993;3(2):71-5.
20. Guanabens 2000 Guanabens N, Farrerons J, Perez-Edo L, Monegal A, Renau A, Carbonell J, et al.Cyclical etidronate versus sodium fluoride in established postmenopausal osteoporosis: a randomized 3 year trial. Bone 2000;27(1):123-8.
21. Gurlek 1997 Gurlek A, Bayraktar M, Gedik O. Comparison of calcitriol treatment with etidronate-calcitriol and calcitonin-calcitriol combinations in Turkish women with postmenopausal osteoporosis: a prospective study. Calcified Tissue International 1997;61(1):39-43.
22. Harris 1993 Harris ST, Watts NB, Jackson RD, Genant HK, Wasnich RD, Ross P, et al.Four-year study of intermittent cyclic etidronate treatment of postmenopausal osteoporosis: three years of blinded therapy followed by one year of open therapy [see comment]. American Journal of Medicine 1993;95(6):557-67.
23. Heaney 1976 Heaney RP, Saville PD. Etidronate disodium in postmenopausal osteoporosis. 1976;20(5):593-604.
24. Heath 2000 Heath DA, Bullivant BG, Boiven C, Balena R. The effects of cyclical etidronate on early postmenopausal bone loss: an open, randomized controlled study. Journal of Clinical Densitometry 2000;3(1):27- 33.
25. Hesch 1988 Hesch RD, Heck J, Delling G, Keck E, Reeve J, Canzler H. Results of a stimulatory therapy of low bone metabolism in osteoporosis with (1-38)hPTH and diphosphonate EHDP. Protocol of study 1. osteoporosis trial Hannover. Klinische Wochenschrift 1988;66(19):976-84.
26. Hodsman 1989 Hodsman A, Adachi J, Olszynski W. Prevention and management of osteoporosis: consensus statements from the Scientific Advisory Board of the Osteoporosis Society of Canada. 6. Use of bisphosphonates in the treatment of osteoporosis [Review] [34 refs]. CMAJ: Canadian Medical Association Journal 1996;155(7):945-8.
27. Hyldstrup 2001 Hyldstrup L, Jorgensen JT, Sorensen TK, Baeksgaard L. Response of cortical bone to antiresorptive treatment. Calcified Tissue International 2001;68(3):135-9.
28. Iwamoto 2001 Iwamoto J, Takeda T, Ichimura S. Effect of menatetrenone on bone mineral density and incidence of vertebral fractures in postmenopausal women with osteoporosis: a comparison with the effect of etidronate. Journal of Orthopaedic Science 2001;6 (6):487-92.
29. Iwamoto 2002 *Iwamoto J, Takeda T, Ichimura S. Beneficial effect of etidronate on bone loss after cessation of exercise in postmenopausal osteoporotic women. American Journal of Physical Medicine & Rehabilitation 2002;81(6):452-7.
30. Iwamoto 2003 a *Iwamoto J, Takeda T, Ichimura S, Uzawa M. Early response to alendronate after treatment with etidronate in postmenopausal women with osteoporosis. Keio Journal of Medicine 2003;52(2):113- 9.
31. Iwamoto 2003 b Iwamoto J, Takeda T, Ichimura S, Matsu K, Uzawa M. Effects of cyclical etidronate with alfacalcidol on lumbar bone mineral density, bone resorption, and back pain in postmenopausal women with osteoporosis. Journal of Orthopaedic Science 2003;8(4):532-7.
32. Jowsey 1971 Jowsey J, Riggs BL, Kelly PJ, Hoffman DL, Bordier P. The treatment of osteoporosis with disodium ethane-1,1-diphosphonate. 1971;78(4):574-84.
33. Mallette 1989 Mallette LE, LeBlanc AD, Pool JL, Mechanick JI. Cyclic therapy of osteoporosis with neutral phosphate and brief, high-dose pulses of etidronate. Journal of Bone and Mineral Research 1989;4(2):143-8.
34. Masud 1998 Masud T, Mulcahy B, Thompson AV, Donnelly S, Keen RW, Doyle DV, Spector TD. Effects of cyclical etidronate combined with calcitriol versus cyclical etidronate alone on spine and femoral neck bone mineral density in postmenopausal osteoporotic women. Annals of the Rheumatic Diseases 1998;57(6):346-9.
35. Miller 1997 Miller PD, Watts NB, Licata AA, Harris ST, Genant HK, Wasnich RD, et al.Cyclical etidronate in the treatment of postmenopausal osteoporosis: efficacy and safety after seven years of treatment [erratum appears in Am J Med 1998 Jun;104(6):608]. American Journal of Medicine 1997;103(6):468-76.
36. Miller 1999 Miller PD, Brown JP, Siris ES, Hoseyni MS, Axelrod DW, Bekker PJ. A randomized, double-blind comparison of risedronate and etidronate in the treatment of Paget's disease of bone. Paget's Risedronate/Etidronate Study Group. 1999;106(5):513-20.
37. Morishige 2003 Morishige K, Yamamoto T, Sawada K, Ohmichi M, Tasaka K, Murata Y. Etidronate and hormone replacement therapy (HRT) for postmenopausal women with osteoporosis despite HRT. Archives of Gynecology & Obstetrics 2003;268(2):105-6.
38. Orme 1994 Orme SM, Simpson M, Stewart SP, Oldroyd B, Westmacott CF, Smith MA, Belchetz PE. Comparison of changes in bone mineral in idiopathic and secondary osteoporosis following therapy with cyclical disodium etidronate and high dose calcium supplementation. Clinical Endocrinology 1994;41(2):245-50.
39. Ott 1994 Ott SM, Woodson GC, Huffer WE, Miller PD, Watts NB. Bone histomorphometric changes after cyclic therapy with phosphate and etidronate disodium in women with postmenopausal osteoporosis. Journal of Clinical Endocrinology and Metabolism 1994;78(4):968-72.
40. Ryan 1994 Ryan PJ, Fogelman I. Clinical experience with etidronate in osteoporosis. Clinical Rheumatology 1994;13(3):455-8.
41. Smith 1989 Smith ML, Fogelman I, Hart DM, Scott E, Bevan J, Leggate I. Effect of etidronate disodium on bone turnover following surgical menopause. Calcified Tissue International 1989;44(2):74-9.
42. Steiniche 1991 Steiniche T, Hasling C, Charles P, Eriksen EF, Melsen F, Mosekilde L. The effects of etidronate on trabecular bone remodeling in postmenopausal spinal osteoporosis: a randomized study comparing intermittent treatment and an ADFR regime. Bone 1991;12(3):155-63.
43. Storm 1996 Storm T, Kollerup G, Thamsborg G, Genant HK, Sorensen OH. Five years of clinical experience with intermittent cyclical etidronate for postmenopausal osteoporosis. Journal of Rheumatology 1996;23(9): 1560-4.
44. Terranova 1999 Terranova R, Luca S. [Treatment of postmenopausal osteoporosis with etidronate] [Italian]. Minerva Medica 1999;90(3):85-90.
45. Wimalawansa 1995 Wimalawansa SJ. Combined therapy with estrogen and etidronate has an additive effect on bone mineral density in the hip and vertebrae: four-year randomized study. American Journal of Medicine 1995;99(1):36-42.
46. Black 2000 Black D. Use of T-Scores to establish comparable diagnostic categories for bone densitiometers [abstract]. NIH Consensus Development Conference on Osteoporosis Prevention, Diagnosis and Therapy. Bethesda (MD): 2000 Mar 27; Bethesda (MD).
47. Black 2000b Black DM, Thompson DE, Bauer DC, Ensrud K, Musliner T, Hochberg MC. Fracture risk reduction with alendronate in women with osteoporosis: the Fracture Intervention Trial. FIT Research Group. Journal of Clinical Endocrinology and Metabolism 2000;85(11):4118-24.
48. Black 2001 Black DM, Steinbuch M, Palermo L, Dargent-Molina P, Lindsay R, Hoseyni MS, Johnell O. An assessment tool for predicting fracture risk in postmenopausal women. Osteoporosis International 2001;12(7):519-28.
49. Brown 2002 Brown JP, Josse RG. 2002 clinical practice guidelines for the diagnosis and management of osteoporosis in Canada. CMAJ 2002;167(10 Suppl):1-34.
50. Browner 1996 Browner WS, Pressman AR, Nevitt MC, Cummings SR. Mortality following fractures in older women. The study of osteoporotic fractures. Archives of Internal Medicine 1996;156(14):1521-5.
51. CADRMP 2005 Canadian Adverse drug Reaction Monitoring Program. Etidronate. In: Health Canada, editor(s). Adverse reaction database. Ottawa: 2005.
52. CADTH 2006 Coyle D, Hadj Tahar A, Murphy G, Perras C, Skidmore B, Boucher M, Husereau D. Teriparatide and Bisphosphonates of Treatment of Osteoporosis In Women: A Clinical and Economic analysis. Canadian Agency for Drugs and Technologies in Health 2006.
53. Cardona 1997 Cardona JM, Pastor E. Calcitonin versus etidronate for the treatment of postmenopausal osteoporosis: a meta-analysis of published clinical trials. Osteoporosis International 1997;7(3):165-74.
54. Cates 2004 Cates C. Visual Rx NNT Calculator 2.0. Dr Chris Cates EBM website. Available from: URL: http://www.nntonline.net/, 2004.
55. Cauley 2000 Cauley JA, Thompson DE, Ensrud KC, Scott JC, Black D. Risk of mortality following clinical fractures. Osteoporosis International 2000;11(7):556-61.
56. Cooper 1993 Cooper C, Atkinson EJ, Jacobsen SJ, O'Fallon WM, Melton LJ, III. Population-based study of survival after osteoporotic fractures. American Journal of Epidemiology 1993;137(9):1001-5.
57. Cranney 2001 Cranney A, Guyatt G, Krolicki N, Welch V, Griffith L, Adachi JD, et al.A meta-analysis of etidronate for the treatment of postmenopausal osteoporosis. Osteoporosis International 2001;12(2):140-51.
58. Cummings 1989 Cummings SR, Black DM, Rubin SM. Lifetime risks of hip, Colles', or vertebral fracture and coronary heart disease among white postmenopausal women. Archives of Internal Medicine 1989;149(11): 2445-8.
59. Dickersin 1994 Dickersin K, Scherer R, Lefebvre C. Identifying relevant studies for systematic reviews. BMJ 1994;309(6964):1286- 91.
60. Doherty 2001 Doherty DA, Sanders KM, Kotowicz MA, Prince RL. Lifetime and five-year age-specific risks of first and subsequent osteoporotic fractures in postmenopausal women. Osteoporosis International 2001;12(1):16-23.
61. Egger 2003 Egger M, Juni P, Bartlett C, Holenstein F, Sterne J. How important are comprehensive literature searches and the assessment of trial quality in systematic reviews? Empirical study. Health Technology Assessment 2003;7(1):1-76.
62. Ettinger 1992 Ettinger B, Black DM, Nevitt MC, Rundle AC, Cauley JA, Cummings SR, Genant HK. Contribution of vertebral deformities to chronic back pain and disability. The Study of Osteoporotic Fractures Research Group. Journal of Bone and Mineral Research 1992;7(4):449-56.
63. Fleisch 1997 Fleisch HA. Bisphosphonates: preclinical aspects and use in osteoporosis. Annals of Medicine 1997;29(1):55-62.
64. Fleiss 1993 Fleiss JL. The statistical basis of meta-analysis. Statistical Methods in Medical Research 1993;2(2):121-45.
65. GRADE 2004 Atkins D, Best D, Briss PA, Eccles M, Falck-Ytter Y, Flottorp S, et al.GRADE Working Group. Grading quality of evidence and strength of recommendations. BMJ 2004;328:1490.
66. Hanley 2003 Hanley DA. Osteoporosis. In: GrayJ editor(s). Therapeutic Choices. 4th Edition. Ottawa: Canadian Pharmaceutical Association, 2003:637-46.
67. Harris 1999 Harris ST, Watts NB, Genant HK, McKeever CD, Hangartner T, Keller M, et al.Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy With Risedronate Therapy (VERT) Study Group. JAMA 1999;282(14):1344-52.
68. Higgins 2005 Higgins JPT, Green S, editors. Cochrane Handbook for Systematic Reviews of Interventions 4.2.5 [updated May 2005]. In: The Cochrane Library, Issue 3, 2005. Chichester, UK: John Wiley & Sons, Ltd.
69. Hodsman 2002 Hodsman AB, Hanley DA, Josse R. Do bisphosphonates reduce the risk of osteoporotic fractures? An evaluation of the evidence to date. CMAJ 2002;166(11):1426-30.
70. Kanis 1994 Kanis JA, Melton LJ, Christiansen C, Johnston CC, Khaltaev N. The diagnosis of osteoporosis. Journal of Bone and Mineral Research 1994;9(8):1137-41.
71. Kherani 2002 Kherani RB, Papaioannou A, Adachi JD. Long-term tolerability of the bisphosphonates in postmenopausal osteoporosis: a comparative review. Drug Safety 2002;25(11):781-90.
72. Lindsay 2001 Lindsay R, Silverman SL, Cooper C, Hanley DA, Barton I, Broy SB, et al.Risk of new vertebral fracture in the year following a fracture. JAMA 2001;285(3):320-3.
73. Mayo Clinic 2005 Alendronate and vertebral fracture risk [multiple letters]. Mayo Clinical Proceedings 2005; Vol. 80:1233-41.
74. McClung 2001 McClung MR, Geusens P, Miller PD, Zippel H, Bensen WG, Roux C, et al.Effect of risedronate on the risk of hip fracture in elderly women. Hip Intervention Program Study Group [see comment]. New England Journal of Medicine 2001;344(5):333-40.
75. Medeffect 2005 Health Canada. Medeffect [website]. Health Canada 2005.
76. Melton 1989 Melton LJ, III, Kan SH, Frye MA, Wahner HW, O'Fallon WM, Riggs BL. Epidemiology of vertebral fractures in women. American Journal of Epidemiology 1989;129(5):1000-11.
77. NIH Consensus 2001 NIH Consensus Development Panel on Osteoporosis Prevention, Diagnosis, Therapy. Osteoporosis prevention, diagnosis, and therapy. JAMA 2001;285(6):785-95.
78. Okeksik 1999 Okeksik A, Shen W, Dawson A, Minshal M, Lips P. The impact of incident vertebral fractures on health-related quality of life in women with prevalent fractures [abstract]. Journal of Bone and Mineral Research 1999;14(Suppl):262.
79. Ross 1994 Ross PD, Davis JW, Epstein RS, Wasnich RD. Pain and disability associated with new vertebral fractures and other spinal conditions. Journal of Clinical Epidemiology 1994;47(3):231-9.
80. Sampson 2003 Sampson M, Barrowman NJ, Moher D, Klassen TP, Pham B, Platt R, et al.Should meta-analysts search Embase in addition to Medline?. Journal of Clinical Epidemiology 2003;56(10):943-55.
81. Shukla 2003 Shukla V. Treating osteoporosis with teriparatide: many unknowns?. Issues in Emerging Health Technologies 2003, issue 51.
82. Silverman 1999 Silverman SL, Minshall ME, Shen W, Harper KD, Xie S. The impact of incident vertebral fractures on health-related quality of life in women with prevalent fractures [abstract]. Journal of Bone and Mineral Research 1999;14(Suppl 1):159.
83. Tugwell 2004 Tugwell P, Shea B, Boers M, Simons L, Strand V, Wells G. Evidence-based Rheumatology. BMJ Books, 2004.
84. WHO 1994 Assessment of fracture risk and its application to screening for postmenopausal osteoporosis: Report of a WHO study group. World Health Organization Technical Report Series 1994;843:1-129.
85. CADTH 2006b Wells GA, Cranney A, Bouchere M, Peterson J, Shea B, Robinson V, Coyle D, Tugwell P. Bisphosphonates for the primary and secondary prevention of osteoporotic fractures in postmenopausal women: a meta-analysis [Technology report no 69]. Ottawa: Canadian Agency for Drugs and Technologies in Health 2006.